The agreement will allow Akorn to manufacture injectable products in finished dosage form for GeneraMedix, who will market these products under the GeneraMedix label. The agreement includes products currently available from Akorn, as well as selected injectable products from the Akorn internal product development pipeline.
“This partnership will allow us to expand our existing market share and increase our contract sales revenues. We believe that GeneraMedix and their executive management team have the experience and infrastructure to successfully market these generic products to the hospital and specialty pharmaceutical markets,” stated Arthur Przybyl, president and CEO of Akorn.
GenraMedix said they were pleased they were able to build on their injectable product portfolio as a result of the deal.
Akorn manufactures and markets sterile specialty pharmaceuticals. GenraMedix is a pharmaceutical company that provides its injectable generic products to the hospital and specialty markets.